NicOx Newswire

Comprehensive Real-Time News Feed for NicOx.

Results 1 - 20 of 20 in NicOx

  1. Nicox announces changes to its Board of DirectorsRead the original story

    Sunday Aug 10 | GlobeNewswire

    Nicox S.A. , the international ophthalmic company, today announces the co-option of Adrienne Graves and Luzi von Bidder to its Board of Directors.

    Comment?

  2. NicOx Sa Focuses U S. Operations On National Launches Of Sjo...Read the original story

    Jul 10, 2014 | BioSpace

    Nicox S.A. , the international ophthalmic company, today announced that Nicox's subsidiary, Nicox Inc, will focus its US sales force on supporting the national roll-out of SjA , an advanced diagnostic panel for the early detection of SjA gren's syndrome in patients with dry eye, and on promoting the RetnaGene portfolio including RetnaGene AMD and ... (more)

    Comment?

  3. Acquisition of Boston biotech for up to $120M a 'validation' of Ora's modelRead the original story w/Photo

    Jul 8, 2014 | Business Journal

    ... firm he spun out seven years ago is validation of the company's model for drug development. French drug developer NiCox S.A. last week announced plans to buy Aciex Therapeutics, a virtual biotech developing an eye drop to treat allergic ...

    Comment?

  4. Acquisition of Boston biotech for up to $120M a 'validation' of Ora's modelRead the original story w/Photo

    Jul 8, 2014 | Business Journal

    ... firm he spun out seven years ago is validation of the company's model for drug development. French drug developer NiCox S.A. last week announced plans to buy Aciex Therapeutics, a virtual biotech developing an eye drop to treat allergic ...

    Comment?

  5. Nicox to Acquire Aciex TherapeuticsRead the original story

    Jul 3, 2014 | Vision Monday

    SOPHIA ANTIPOLIS, France- Nicox S.A. , based here, announced on July 2 that it has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics , a private, U.S.-based, ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including ... (more)

    Comment?

  6. NicOx SA Scoops Up Aciex Therapeutics In $120 Million DealRead the original story

    Jul 2, 2014 | BioSpace

    Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including lead program AC-170 in phase 3 for allergic conjunctivitis Transaction, subject to the approval of Nicox's shareholders, includes a $65 million upfront payment in newly issued Nicox shares, plus contingent value rights giving right to shares, for a potential ... (more)

    Comment?

  7. Nicox to acquire Aciex Therapeutics, Inc.Read the original story

    Jul 1, 2014 | GlobeNewswire

    Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including lead program AC-170 in phase 3 for allergic conjunctivitis Transaction, subject to the approval of Nicox's shareholders, includes a $65 million upfront payment in newly issued Nicox shares, plus contingent value rights giving right to shares, for a potential ... (more)

    Comment?

  8. NicOx SA Launches Commercial Operations In GermanyRead the original story

    Jun 30, 2014 | BioSpace

    Nicox S.A. , the international ophthalmic company, today announced the launch of its German operations.

    Comment?

  9. Nicox And Sequenom Announce The Launch Of Expanded Access To RetnaGenea Test Portfolio In The U.S.Read the original story w/Photo

    Jun 20, 2014 | Laboratory Network .com

    Technopole de Sophia Antipolis France and SAN San Diego, CA /PRNewswire/ - Nicox S.A. , the international ophthalmic company, and Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene portfolio of ... (more)

    Comment?

  10. Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolioRead the original story w/Photo

    Jun 19, 2014 | Medical News

    Nicox S.A. , the international ophthalmic company, and Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene portfolio of laboratory-developed genetic tests in the United States .

    Comment?

  11. NicOx SA And Sequenom Inc. Announce The Launch Of Expanded Access To...Read the original story

    Jun 19, 2014 | BioSpace

    Nicox S.A. , the international ophthalmic company, and Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene portfolio of laboratory-developed genetic tests in the United States .

    Comment?

  12. NicOx SA: Santen, Inc. Grants EuPharmed Extension Of Exclusive Rights ...Read the original story

    May 30, 2014 | BioSpace

    Nicox S.A. today issued a revised version of the press release dated May 28, 2014, to correct the number of newly issued Nicox shares to be paid to Fin Posillipo SPA in relation to the extension of the CationormA distribution agreement in Italy.

    Comment?

  13. Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm(R) in ItalyRead the original story

    May 27, 2014 | GlobeNewswire

    Nicox S.A. , the international ophthalmic company, today announces that its wholly-owned Italian subsidiary Eupharmed has entered into an exclusive agreement with Santen SAS, enabling Eupharmed to continue to distribute Cationorm in Italy.

    Comment?

  14. Nicox: first quarter 2014 financial informationRead the original story

    May 15, 2014 | GlobeNewswire

    Nicox S.A. , the international ophthalmic company, today provides an update on its first quarter 2014 revenues and cash position.

    Comment?

  15. Nicox: first quarter 2014 financial informationRead the original story

    May 15, 2014 | Hispanic Business

    ... hypertension. Further NO-donors are under development, notably through partners. or its products please visit www.nicox.com . ................................... This press release contains certain forward-looking statements. Although the Company ...

    Comment?

  16. NicOx SA Launches Adenoplus And Xailin Dry Eye Product Range In EuropeRead the original story

    Mar 17, 2014 | BioSpace

    Nicox S.A. today announced the European launch of Xailin , a new range of tear lubricants for relief of dry eye symptoms, and of AdenoPlusA , an in vitro diagnostic medical device to help the differential diagnosis of acute conjunctivitis.

    Comment?

  17. Nicox launches AdenoPlus(R) and Xailin(TM) dry eye product range in EuropeRead the original story

    Mar 16, 2014 | GlobeNewswire

    Nicox S.A. today announced the European launch of Xailin , a new range of tear lubricants for relief of dry eye symptoms, and of AdenoPlus , an in vitro diagnostic medical device to help the differential diagnosis of acute conjunctivitis.

    Comment?

  18. NicOx S.A. (COX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Report AvailableRead the original story

    Mar 2, 2014 | PR-inside.com

    2014-03-02 12:48:05 - Fast Market Research recommends "NicOx S.A. (COX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" from GlobalData, now available NicOx S.A. (NicOx) is a healthcare company. It carries out the development and ...

    Comment?

  19. Nicox to re-focus Naproxcinod on Duchenne Muscular DystrophyRead the original story

    Feb 14, 2014 | Drugs.com

    February 14, 2014 -- Nicox S.A. today announced its decision to re-focus naproxcinod development efforts.

    Comment?

  20. NicOx SA To Re-Focus Naproxcinod On Duchenne Muscular DystrophyRead the original story

    Feb 14, 2014 | BioSpace

    ... evaluation will be entirely funded by this partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right, should the results of the evaluation be satisfactory to the ...

    Comment?